Bengt Lindbom-Johansson

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study.

Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study.

Journal: The Lancet. Infectious diseases

Published: August 12, 2025

Safety and immunogenicity of a single booster dose of the group B streptococcus AlpN candidate vaccine (GBS-AlpN) in previously vaccinated healthy women compared with a single dose in previously unvaccinated women.

Safety and immunogenicity of a single booster dose of the group B streptococcus AlpN candidate vaccine (GBS-AlpN) in previously vaccinated healthy women compared with a single dose in previously unvaccinated women.

Journal: Vaccine

Published: June 26, 2025

Protection acquired upon intraperitoneal group a Streptococcus immunization is independent of concurrent adaptive immune responses but relies on macrophages and IFN-γ.

Protection acquired upon intraperitoneal group a Streptococcus immunization is independent of concurrent adaptive immune responses but relies on macrophages and IFN-γ.

Journal: Virulence

Published: February 08, 2025

Insertion of an immunodominant T helper cell epitope within the Group A Streptococcus M protein promotes an IFN-γ-dependent shift from a non-protective to a protective immune response.

Insertion of an immunodominant T helper cell epitope within the Group A Streptococcus M protein promotes an IFN-γ-dependent shift from a non-protective to a protective immune response.

Journal: Frontiers in immunology

Published: June 16, 2023

Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations.

Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations.

Journal: Frontiers in immunology

Published: September 22, 2022

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial.

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial.

Journal: iScience

Published: July 01, 2022

Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.

Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.

Journal: Vaccine

Published: June 21, 2022

Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages.

Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages.

Journal: Frontiers in immunology

Published: April 29, 2022

A Recombinant Alpha-Like Protein Subunit Vaccine (GBS-NN) Provides Protection in Murine Models of Group B Streptococcus Infection.

A Recombinant Alpha-Like Protein Subunit Vaccine (GBS-NN) Provides Protection in Murine Models of Group B Streptococcus Infection.

Journal: The Journal of infectious diseases

Published: March 02, 2022

Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.

Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.

Journal: Frontiers in immunology

Published: November 11, 2021

A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains.

A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains.

Journal: Cell reports. Medicine

Published: September 09, 2021

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.

Journal: Vaccine

Published: February 24, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026